Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
16.64
+2.04 (13.97%)
At close: Oct 13, 2025, 4:00 PM EDT
16.64
0.00 (0.00%)
After-hours: Oct 13, 2025, 6:30 PM EDT
Arcus Biosciences Employees
Arcus Biosciences had 627 employees as of December 31, 2024. The number of employees increased by 50 or 8.67% compared to the previous year.
Employees
627
Change (1Y)
50
Growth (1Y)
8.67%
Revenue / Employee
$417,863
Profits / Employee
-$475,279
Market Cap
1.77B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 627 | 50 | 8.67% |
| Dec 31, 2023 | 577 | 77 | 15.40% |
| Dec 31, 2022 | 500 | 134 | 36.61% |
| Dec 31, 2021 | 366 | 130 | 55.08% |
| Dec 31, 2020 | 236 | 97 | 69.78% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RCUS News
- 1 day ago - Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study - Business Wire
- 4 days ago - Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
- 6 days ago - Arcus Biosciences, Inc. (RCUS) Shareholder/Analyst Call Transcript - Seeking Alpha
- 7 days ago - Why Is Arcus Biosciences Stock Trading Higher On Monday? - Benzinga
- 7 days ago - Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event - Business Wire
- 4 weeks ago - Arcus Biosciences, Inc. (RCUS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Arcus Biosciences, Inc. (RCUS) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 5 weeks ago - Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation - Business Wire